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Abstract
A deficiency of plasmalogens, caused by impaired peroxisomal metabolism affects normal development and multiple organs
in adulthood. Treatment options aimed at restoring plasmalogen levels may be relevant for the therapy of peroxisomal and
non-peroxisomal disorders. In this study we determined the in vivo efficacy of an alkyl glycerol (AG), namely, 1-O-octadecyl-
rac-glycerol, as a therapeutic agent for defects in plasmalogen synthesis. To achieve this, Pex7 knockout mice, a mouse model
for Rhizomelic Chondrodysplasia Punctata type 1 characterized by the absence of plasmalogens, and WT mice were fed a
control diet or a diet containing 2% alkyl-glycerol. Plasmalogen levels were measured in target organs and the biochemical
data were correlated with the histological analysis of affected organs. Plasmalogen levels in all peripheral tissues of Pex7 KO
mice fed the AG diet for 2 months normalized to the levels of AG fed WT mice. In nervous tissues of Pex7 KO mice fed the AG-
diet, plasmalogen levels were significantly increased compared to control fed KO mice. Histological analysis of target organs
revealed that the AG-diet was able to stop the progression of the pathology in testis, adipose tissue and the Harderian gland.
Interestingly, the latter tissues are characterized by the presence of lipid droplets which were absent or reduced in size and
number when ether-phospholipids are lacking, but which can be restored with the AAG treatment. Furthermore, nerve
conductioninperipheralnerveswasimproved.When givenpriortothe occurrenceofmajorpathologicalchanges,theAG-diet
prevented or ameliorated the pathology observed in Pex7 KO mice depending on the degree of plasmalogen restoration. This
study provides evidence of the beneficial effects of treating a plasmalogen deficiency with alkyl-glycerol.
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Introduction
Ether-phospholipids are major constituents of cellular membranes
and are characterized by an ether-bond at the sn-1 position of the
glycerol backbone. Ether-phospholipids are divided into two groups,
the distinctive featurebeing the presenceof eithera 1-O-alkylor1-0-
alkenyl side-chain at sn-1. Plasmalogens represent the ether-
phospholipids with a vinyl-ether linkage (alkenylacyl-glyceropho-
spholipids) whereas platelet-activating factor (PAF) is a typical
example of the ether-phospholipids with an 1-O-alkyl ether linkage
(alkylacyl-glycerophospholipids) [1,2]. The biosynthetic pathway of
ether-phospholipids, involves several enzymatic steps performed in
peroxisomes and the endoplasmatic reticulum [3,4]. A genetic
deficiencyaffecting eitherthe biogenesisofperoxisomes or oneof the
twoperoxisomalenzymes,i.e.glyceronephosphateO-acyltransferase
(Gnpat) and alkylglycerone phosphate synthase (Agps) involved in
ether-phospholipid biosynthesis, leads to absent or reduced levels of
ether-phospholipids [5–8]. In human peroxisomal disorders, the
measurement of plasmalogen levels is the hallmark for diagnosis,
whereas the levels of PAF have not been fully investigated [9–12]. In
mammals, the distribution and composition of plasmalogens varies
between different tissues with brain, kidney and testes having
relatively high levels of plasmalogens.
Plasmalogens contain at the sn-1 position a long chain alcohol
composed of either C16:0, C18:0 or C18:1, whereas the sn-2
position contains a polyunsaturated fatty acid (e.g. docosahex-
aenoic acid, arachidonic acid) [3]. Plasmalogens have been
implicated in several biological processes and have been shown
to mediate fluidity, signal transduction and to protect against
oxidative stress [13,14]. The human peroxisomal disorder
Rhizomelic Chondrodysplasia Punctata (RCDP) type 1 [15,16],
caused by mutations in the PEX7 gene is characterized by a
clinical presentation that includes congenital cataracts, proximal
shortening of long bones, contractures and hypotonia [17–19].
The deficiency in PEX7, which encodes the receptor for
peroxisomal proteins containing a peroxisomal targeting signal
type 2 (PTS2) impairs the import of three peroxisomal proteins,
namely acetyl-CoA acyltransferase 1 (Acaa1), phytanoyl-CoA 2-
hydroxylase (Phyh) and Agps [20–22]. Despite this triple
deficiency, the main pathophysiological factor in RCDP type 1
patients is the severe deficiency in the biosynthesis of plasmalo-
gens, due to the absence of Agps from peroxisomes [23–25].
Indeed, strikingly similar clinical features are seen in two other
forms of RCDP, namely type 2 and type 3, as caused by mutations
in GNPAT and AGPS, respectively [5,26]. All types of RCDP share
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deficiency in ether-phospholipids is the major cause of tissue
pathology and disease state, and highlight the importance of
plasmalogens for human health. In RCDP type 1, the absence of
Phyh from peroxisomes causes, in addition, a defect in the a-
oxidation of phytanic acid [27]. Since both phytanic acid and its
precursor (phytol) are solely derived from dietary sources, phytanic
acid levels in RCDP type 1 patients may vary depending on the
diet and age of diagnosis [15,28–30]. Since high levels of phytanic
acid lead to Purkinje cell death, ataxia, retinitis pigmentosa and
peripheral neuropathy [31–33], the accumulation of phytanic acid
in RCDP type 1 patients may worsen tissue pathology and disease
progression [34]. The absence of Acaa1 from peroxisomes in
RCDP type 1 does not seem to have a generalized metabolic
consequence in very-long-chain fatty acid b-oxidation, since levels
of VLCFA in plasma and fibroblasts are normal [35–37].
Nevertheless, the defect in Acaa1 may be tissue and cell dependent
since increased levels of VLCFA have been observed in some
blood cells [37].
Alkyl-glycerols (AG) can enter the plasmalogen biosynthetic
pathway downstream of the peroxisomal steps and, when added to
cultured cells, have been shown to restore plasmalogen levels[38,39].
AG have been administered to patients with Zellweger syndrome, the
most severe peroxisomal disorder in which all metabolic functions of
peroxisomes are defective, but clinical improvement was difficult to
evaluate since Zellweger patients have a myriad of other metabolic
defects that modulate the disease [40,41].
In this study we evaluated the efficacy of AG in rescuing the
biochemical defects and the pathology caused by the deficiency in
plasmalogens. We used the Pex7 knockout (KO) mouse, as it has a
complete deficiency in the biosynthesis of ether-phospholipids and
displays all the pathological hallmarks of the human disorder [42].
The deficiency in plasmalogens characteristic of Pex7 KO mice is
due to the impaired import of AGPS into peroxisomes. Similarly
to RCDP type 1, Pex7 KO mice also have an impairment in the
import of Phyh and Acaa1. Despite this triad of import
deficiencies, the phenotype of Pex7 KO is primarily, if not solely,
due to the defect in plasmalogens since it closely resembles that of
the Gnpat KO mouse [43]. Moreover, under standard dietary
regiments the Pex7 KO mice do not accumulate phytanic acid and
the accumulation of VLCFA is age and tissue dependent [42,44].
In this study we evaluated the efficacy of AG in rescuing the
biochemical defect and the pathology caused by a deficiency of
plasmalogens. We fed WT and Pex7 KO mice a diet containing
the AG, i.e. 1-O-octadecyl-rac-glycerol, and found that compared
to the control diet, the AG diet increased plasmalogen levels in
Pex7 KO mice and therefore can be used in vivo to restore
plasmalogen levels. Moreover, the restoration of plasmalogen
levels could halt or at least slow down the progression of the
pathology in several target organs depending on the pathological
status of the target tissues at the time of the therapeutic
intervention. Our results demonstrate the benefits/effects of AG
as a therapeutic agent in diseases in which there is a defect in
ether-phospholipid biosynthesis.
Results
Alkyl-glycerol supplementation to Pex7 KO mice rescues
plasmalogen deficiency
To determine whether AG could restore the plasmalogen
deficiency present in Pex7 KO mice, we fed mice either a control
diet or a diet containing 2% 1-O-octadecyl-rac-glycerol (AG diet)
for 2 months. In Pex7 KO mice fed the AG diet, plasmalogen
levels increased from undetectable to the levels found in control-
fed or AG-fed wild type mice in erythrocytes and in several tissues
including kidney, heart and eye (Table 1). These results indicate
that in these tissues the AG diet could restore plasmalogens to the
physiological steady-state level. In contrast, the AG diet only
marginally increased plasmalogen levels in nervous tissues. In the
peripheral nervous system (PNS), measurement of plasmalogens in
sciatic nerves revealed that in Pex7 KO fed the AG diet
plasmalogen levels increased to 2.3% of WT levels (Table 1). In
the central nervous system (CNS), measurement of plasmalogens
in cerebrum and cerebellum revealed marginal increases to 0.7%
and 1.4% of WT level, respectively, whereas in spinal cord no
increase was observed. In order to test if longer treatment periods
could increase the plasmalogen levels in CNS tissues we fed Pex7
KO mice the AG diet for 4 months (Table 1). After this prolonged
treatment, plasmalogen levels in spinal cord and cerebellum of
treated Pex7 KO mice were higher than after the 2 month
treatment period, displaying 2.9% of WT levels. These results
indicate that AG can be used to increase plasmalogen levels in vivo
and that different treatment periods should be considered
depending if the target is systemic or nervous tissue.
Alkyl-glycerol supplementation to Pex7 KO mice
improves the pathology of affected tissues
Next, we determined the effects of the AG diet on the pathology
observed in Pex7 KO mice. Testicular atrophy primarily caused by
loss of cells from the spermatogonia lineage is one of the hallmarks
of the pathology caused by deficiencies in the biosynthesis of
plasmalogens in mice [44,45]. Histological evaluation of seminif-
erous tubules from Pex7 KO mice on control diet showed a Sertoli-
only phenotype, with the seminiferous epithelium solely populated
by Sertoli cells and devoid of spermatogonia and spermatocytes
(Fig. 1A). Treatment of Pex7 KO mice with the AG diet for 2
months restored plasmalogen levels in the testis and ameliorated
Table 1. Plasmalogen levels in different tissues after control
and AG-diet feeding.
Control diet AG diet
Period Sample WT KO WT KO
2 months RBC 4.260.2 0.160.1 7.660.7 5.460.3
Liver 0.560.1 N.D. 1.160.1 1.460.1
Kidney 3.560.2 N.D. 7.160.5 3.960.2
Heart 2.360.4 N.D. 9.861.6 9.661.1
Lung 8.160.9 N.D. 15.762.1 17.763.2
Testis 2.460.1 N.D. 3.460.2 2.160.5
Eye 4.060.1 N.D. 3.160.6 2.760.2
Sciatic nerve 26.767.1 N.D. 3961.5 0.660.12
Cerebrum 13.762.8 N.D. 13.961.9 0.160.1
Cerebellum 14.561.0 N.D. 14.5 60.5 0.260.1
Spinal cord 21.366.1 N.D. 20.165.1 N.D.
4 months Cerebellum N.P. N.P. 13.760.8 0.460.06
Spinal cord N.P. N.P. 17.262.8 0.560.1
Plasmalogen levels are expressed as mean 6 S.D of the percentages of
dimethylacetal (DMA) derivatives of C18:0 to the corresponding saturated fatty
acid.
Numbers of mice tested: on control diet WT mice (n=4) and Pex7 KO mice
(n=3) and on AG diet for 2 months WT mice (n=6) and Pex7 KO mice (n=6); for
4 months WT (n=3) and Pex7 KO mice (n=3). RBC- red blood cells; AG- alkyl-
glycerol diet; N.D.- not detected; N.P.- not performed.
doi:10.1371/journal.pone.0028539.t001
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spermatocytes at different stages of maturation in the seminiferous
epithelium (Fig. 1A), which is indicative of a restoration in
spermatogenesis. Regardless of the histological improvement,
however, mature spermatozoa were not detected in the seminif-
erous tubules or in the epididymis (data now shown).
The Harderian gland synthesizes lipids, porphyrins and indoles
for pheromonal and lubricatory purposes, and has been implicated
in, amongst others, thermoregulatory and photoreceptor protec-
tion processes [46]. The lipids which are enriched in alkylglycerols
are stored in numerous small droplets and are subsequently
excreted (Fig. 1B). Harderian glands contain peroxisomes [47,48]
and show gross abnormalities in case of peroxisomal dysfunction
(Brites et. al. unpublished results, Fig. 1B and Fig. 2A). Histological
examination of Harderian glands from Pex7 KO mice showed
atrophic secretory cells with reduced cytoplasm, lacking the
characteristic lipid inclusions found in Harderian glands of WT
mice (Fig. 1B and Fig. 2A). Treatment of Pex7 KO mice with the
AG diet for 2 months improved the histology of the Harderian
gland with secretory cells showing small lipid droplets and an
increase in the cytoplasmic volume (Fig. 1B).
It is quite striking that also adipose tissue, which is the most
important storage of lipids in the body, is abnormal in plasmalogen
deficient mice [44]. Epididymal, inguinal, retroperitoneal and
subscapular white adipose tissue (WAT) depots are extremely
reduced, whereas the sizes of the dorsal brown fat pads are
normal. Histological analyses of lipids in brown adipose tissue
(BAT) from WT and Pex7 KO mice (Fig. 1D and Fig. 2A)
revealed abnormally small lipid droplets within the cytoplasm of
individual adipocytes. The extremely reduced WAT and abnor-
mal histology of BAT was not due to a reduced food intake (WT
5.860.5 g/day; Pex7 KO 4.960.8 g/day; non-significant differ-
ence with p=0.1). Analysis by western blot of uncoupling protein
1 (UCP1) in BAT and WAT of WT and Pex7 KO mice, did not
reveal any differences (Fig. 2B), suggesting that in Pex7 KO mice
there is no deregulation of uncoupling activity that would explain
the loss of WAT and the lipolysis-like phenotype of BAT.
To obtain further evidence that lipid droplet abnormalities are
caused by ether-phospholipid deficiency, we performed a
histological assessment in the Harderian gland and BAT of Gnpat
KO mice and WT littermates (Fig. 2C). Gnpat KO mice are
characterized by a unique defect in the biosynthesis of plasmal-
ogens [43]. The histological analyses showed that the Harderian
gland of mutant mice is devoid of the characteristic lipid
inclusions, similar to Pex7 KO mice. In addition, BAT from
Gnpat KO mice also showed partitioned fat deposits and
Figure 1. Therapeutic effects of AG diet on rescuing the pathology caused by plasmalogen deficiency. (A) Testis sections stained with
hematoxylin and eosin (H&E). Seminiferous tubules from control-fed Pex7 KO mice have no spermatocytes and display a Sertoli-only phenotype,
whereas seminiferous tubules from AG-fed Pex7 KO mice display a stratified epithelium with spermatocytes at different stages of maturation. Bars are
10 mm. (B) Harderian gland sections stained with H&E. After AG diet, Harderian glands from Pex7 KO mice showed a restoration in morphology that
included the appearance of small lipid inclusions (arrowheads) and increased size of glandular cells. Bars are 10 mm. (C) White adipose tissue sections
stained with H&E. Degenerated adipocytes with small-sized fat inclusions are characteristic features found in Pex7 KO mice. After AG diet, adipocytes
from Pex7 KO mice displayed normal size and fat content. Bars are 25 mm. (D) Brown adipose tissue sections stained with H&E. Adipocytes from
control-fed Pex7 KO mice showed, in contrast to WT, an increased number of small fat inclusions within the cytoplasm of adipose cells. AG-diet
restored the histology of adipocytes in brown adipose tissue of Pex7 KO mice. Bars are 10 mm. Numbers of mice analyzed from two independent
cohorts: on control diet WT mice n=4 and Pex7 KO mice n=3, on AG diet WT mice n=6 and Pex7 KO mice n=6.
doi:10.1371/journal.pone.0028539.g001
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defects in the biosynthesis of plasmalogens share the same lipid
abnormalities in Harderian glands and adipose tissues, our results
suggest a role of plasmalogens in lipid droplet formation and/or
maintenance.
Based on these findings, adipose tissue was also used to evaluate
the efficacy of the AG diet in Pex7 KO mice. The AG diet
normalized the histological appearance of white adipocyte size and
fat deposition in Pex7 KO mice (Fig. 1C), and also produced
beneficial effects on brown adipocytes, characterized by the
increased size of lipid inclusions (Fig. 1D). This was accompanied
by a significant increase in body weight of Pex7 KO mice. Indeed,
on a normal diet the mutant mice weighed considerably less that
WT mice (22.0 gr 61.1 (n=3) vs. 33.3 gr 61.5 (n=4)
p=0.0014). Feeding the AG diet for 2 months led to an increase
in body weight of Pex7 KO mice (KO 28.7 gr 61.7 (n=6); WT
32.3 gr 61.8 (n=6)) representing a 30% gain (p=0.0048) when
compared to untreated Pex7 KO mice.
Taken together, the results obtained highlight the importance of
plasmalogens in the accumulation of lipid inclusions in Harderian
glands and adipose tissue. To further evaluate the role of
plasmalogens in lipid droplet formation, we prepared mouse
embryonic fibroblasts (MEFs) from WT and Gnpat KO E13.5
embryos. Analysis of lipid droplets under normal culture
conditions showed that, plasmalogen-deficient MEFs had fewer
and smaller lipid droplets when compared to WT MEFs (Fig.3A–
C). The in vitro treatment of Gnpat KO MEFs with 15 mM AG, led
to a restoration of the number and volume of lipid droplets
(Fig. 3A–C). These results indicate that plasmalogens are
important for lipid droplet homeostasis, and that treatment with
AG can rescue the defects in lipid droplet formation.
We also evaluated the effects of the AG diet on the functioning
of peripheral nerves since we observed an increase in plasmalogen
levels after the AG diet. We found that Pex7 KO mice develop a
peripheral neuropathy with reduced motor nerve conductance
velocity (MNCV). On the control diet, Pex7 KO mice showed
increased latencies of compound muscle action potentials
(CMAPs) (Fig. 4A) that resulted in a 37% reduction in MNCV
when compared to WT mice on the control diet (Fig. 4B). Pex7
KO mice on the AG diet showed an improvement in CMAP
latencies (Fig. 4A) that resulted in an increase in MNCV. Although
the AG diet did not restore the MNCV of Pex7 KO mice to
normal values, it clearly improved nerve conduction, with KO
mice having only a 19% reduction in MNCV when compared to
WT mice (Fig. 4B).
Figure 2. Lipid rich tissues are affected by a deficiency in
plasmalogens. (A) Lipid staining of BAT (upper panels) and Harderian
glands (bottom panels) from 3 months old WT and Pex7 KO mice.
Adipocytes from Pex7 KO mice, showed portioning of the lipid
inclusions with smaller lipid droplets. The secretory cells in the
Harderian glands from Pex7 KO mice were characterized by an
extremely reduced content of lipid inclusions. Bars are 25 mm. (B)
Western blot analyses of UCP1 expression in BAT and WAT lysates from
3 months old WT and Pex7 KO mice. Analysis of b-action was used as
loading control. In BAT the characteristic high levels of UCP1 expression
did not differ in Pex7 KO samples. In WAT, the considerable reduced
expression of UCP1 was not altered in lysates from Pex7 KO mice,
indicating no major disturbances in lypolysis that could explain the
altered histological appearance of BAT and WAT. (C) Histological
assessment with hematoxylin and eosin (H&E) staining of Harderian
gland and BAT from 3 months old WT and Gnpat KO mice. Gnpat KO
mice have a defect in the biosynthesis of plasmalogens, and also display
the loss of lipid inclusions in Harderian glands (upper panels) and
abnormal brown adipocytes (bottom panels), with irregular and smaller
lipid droplets. Bars are 25 mm.
doi:10.1371/journal.pone.0028539.g002
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28539Figure 3. Deficiency in plasmalogens affects lipid droplet formation in MEFs. (A) Lipid droplets were stained with BODIPY 493/503 in MEFs
from WT and Gnpat KO mice (n=4 per genotype). MEFs were cultured in normal medium (upper panels), in control medium (bottom left panel) or in
medium supplemented with 15 mM AG (bottom right panel). In MEFs from Gnpat KO mice, the deficiency in plasmalogens leads to a reduction in the
number and volume of lipid droplets (B, C). Treated of Gnpat KO MEFs with 15 mM AG for 7 days lead to an increase in the number and volume of
lipid droplets (B, C) to values similar to those of lipid droplets from WT MEFs. * p,0.02 using Mann Whitney test.
doi:10.1371/journal.pone.0028539.g003
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observed after the treatment with the AG diet can ameliorate the
pathology in testis and Harderian gland. Treatment with the AG
diet also restored adipose tissue morphology and let to improved
nerve function of Pex7 KO mice. In addition, the observed defect
in lipid droplets of MEFs from Gnpat KO mice could also be
reverted with the in vitro AG-treatment.
Alkyl-glycerol treatment before onset of pathology
Our combined results indicate that the AG diet had dual
beneficial effects since it not only restores plasmalogen levels but it
also improved the histopathological alterations in target organs of
Pex7 KO mice. This led us to investigate if the AG diet could also
be used to prevent the pathology caused by plasmalogen
deficiency. To achieve this, we fed the control or AG diet to
pregnant dams and determined the effects on 20-day old pups
(P20). Regardless of the diet fed to the dams, Pex7 KO pups were
born hypotonic and measurements of body weight during the first
2 postnatal weeks showed a significant difference when compared
to WT pups (20% reduction in body weight; p=0.005), which
suggests that AG did not cross the placental barrier and/or was
not present in milk during lactation. Nevertheless, after the second
postnatal week the weight of Pex7 KO pups from the AG diet
increased to reach that of WT pups (with KO mice having only 5
to 12.5% reduction in body weights when compared to WT mice;
p=0.726). Combined with the previous results of increased body
weight gain from the dietary regimen on adult mice, these results
suggest that the increase in body weight of Pex7 KO pups starts
upon the oral ingestion of the AG diet.
Measurement of plasmalogen levels showed that the AG diet led
to increased plasmalogen levels in multiple tissues of Pex7 KO pups
(Fig. 5). The restoration of plasmalogen levels in systemic tissues
from Pex7 KO pups varied between 45 and 65% of the WT levels.
This partial restoration of plasmalogens was likely due to the
source of AG in Pex7 KO pups which was primarily diet-derived
and the pups ingested the AG diet for a period of maximally 6
days. The undetectable levels of plasmalogens in cerebrum of AG-
treated Pex7 KO mice are likely due to the short period of
treatment, since the increases in plasmalogens observed in older
mice required a treatment for 2 or 4 months (Table 1).
Next, we determined the effects of the AG diet on the
histopathology of Pex7 KO pups. At P20, testis of Pex7 KO pups
fed the control diet showed disorganization of the seminiferous
epithelium with loss of spermatocytes (Fig. 6A), whereas Pex7 KO
pups fed the AG diet showed normal seminiferous tubules without
loss of spermatocytes (Fig. 6A) indicating that the 42% restoration
in plasmalogen levels (Fig. 5) could prevent testicular degeneration.
The AG diet also prevented the development of cataracts in
Pex7 KO pups. Whereas Pex7 KO pups fed a control diet showed
bilateral cataracts as soon as the pups opened the eye lids (age P14-
P15), AG-fed Pex7 KO pups failed to develop cataracts or
developed a unilateral small nuclear cataract (Fig. 6B). The
presence and the extent of the cataract in AG-fed Pex7 KO pups
correlated with the amount of plasmalogens measured in the eye
(Fig. 6C).
These results indicate that an early increase in plasmalogen
levels can prevent the development and progression of tissue
pathology.
Discussion
As highlighted by the clinical presentation of RCDP patients,
ether-phospholipid deficiency has major consequences for tissue
development and organ function [19]. Therefore any therapeutic
intervention aimed at restoring ether-phospholipid levels should
have a beneficial effect. In recent years deficiencies in plasmalogen
levels have been observed in other peroxisomal diseases as well as
non-peroxisomal disorders [49–52], which increases the need for
the development and implementation of a method to increase
plasmalogen levels.
In vitro studies have shown that alkyl-glycerols are able to enter
the plasmalogen biosynthetic pathway after the initial peroxisomal
steps, and restore plasmalogen levels [38,53,54]. AG also have
other beneficial advantages that include reduced side effects of
radiotherapy, inhibition of tumor growth, and stimulation of the
immune system [55]. Nevertheless, their in vivo application as
precursors of plasmalogens has remained limited [40,56,57]. Using
the Pex7 KO mouse as a model for RCDP type 1 and as a model
characterized by a complete deficiency of ether-phospholipids, we
Figure 4. Nerve conduction improves after AG treatment. (A)
Representative examples of compound muscle action potentials
recordings after stimulation at the sciatic notch of wild type and Pex7
KO mice fed control or AG diets. Increased latencies were observed in
control-fed Pex7 KO mice that were partially restored after the AG diet.
(F) Calculated motor nerve conduction velocities (MNCV) of wild type
and Pex7 KO mice fed control or AG diets. Bars represent the average
values obtained after bilateral measurements in wild type and Pex7 KO
mice, and the significance is shown above each comparison. The AG
diet partially restores MNCV in sciatic nerves of Pex7 KO mice. Numbers
of mice analyzed: on control diet WT mice n=4 and Pex7 KO mice n=3,
on AG diet WT mice n=4 and Pex7 KO mice n=4.
doi:10.1371/journal.pone.0028539.g004
Alkyl-Glycerol Rescue of Plasmalogen Defects
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28539have evaluated the in vivo effectiveness of AG as a plasmalogen
precursor and as a therapeutic agent. Treatment of WT and Pex7
KO mice with the AG 1-O-octadecyl-rac-glycerol led to the
restoration of plasmalogens containing a C18:0 moiety at the sn-1
position of the glycerol backbone. The most abundant forms of
plasmalogens are those containing either a C16:0 or a C18:0 at the
sn-1 position. Using 1-O-octadecyl-rac-glycerol as a precursor we
rescued the plasmalogen form containing the C18:0 moeity. The
importance or functionality of the different forms of plasmalogens
is not well established, but our work suggests that the combination
of different AG, e.g. a mixture of 1-O-octadecyl-rac-glycerol with
1-O-hexadecyl-rac-glycerol, would be able to rescue the two most
abundant forms of plasmalogens containing C18:0 and C16:0
moieties, respectively. In our setup we used a diet supplemented
with 2% w/w AG, which translates to a daily dosage of 80mg AG
per mouse per day. The diet was well tolerated as judged by visual
inspection of mice and the biochemical, histological and functional
assessments performed. Recently, Braverman et al., reported the
generation of a hypomorphic Pex7 mouse, and evaluated the
ability of the AG 1-O-octadecyl-rac-glycerol to rescue plasmalogen
levels in erythrocytes [57]. In contrast to the Pex7 KO mouse, in
which plasmalogens levels are undetectable, the hypomorphic Pex7
model shows on average a 50-60% decrease in plasmalogen levels.
The AG diet (1mg AG per mouse per day) increased but did not
normalize plasmalogen levels in erythrocytes of hypomorphic Pex7
mice [57]. This is possibly due to the low dosage of AG used. In
addition, 1-O-octadecyl-rac-glycerol can undergo oxidative cleav-
age of its alkyl bond by the action of glyceryl-ether monooxygen-
ase [58], which can decrease the availability of AG for the
biosynthesis of plasmalogens. In our study, the use of a higher
dosage of AG, may circumvent the loss of 1-O-octadecyl-rac-
glycerol through the actions of glyceryl-ether monooxygenase
and/or lysophospholipases. In humans well tolerated dosages of
AG range from 5–50 mg/kg [40], and the dietary supplements of
shark liver oils may contain up to 200 mg of AG.
In systemic tissues of adult Pex7 KO mice, the AG diet was able
to restore plasmalogen levels to physiologic levels, showing its
efficacy as a plasmalogen precursor. Nevertheless, the inefficient
rescue of plasmalogen levels in nervous tissue by the AG diet
remains to be addressed. In the CNS, the blood-brain barrier and/
or the increased catabolism of newly formed plasmalogens, with
half-lives of less than 1 hour [59], as well as the metabolic
heterogeneity found within different areas of the brain towards
plasmalogen biosynthesis may explain the inability of the AG diet
to normalize plasmalogen levels [40,59,60]. Moreover, since
nervous tissues is highly enriched in plasmalogens, longer
treatment periods may be necessary to overcome the turnover
rates and to reach steady-state physiologic levels. In the PNS we
observed an improvement of the neuropathic condition in Pex7
KO mice treated with the AG diet, despite marginal increases in
plasmalogens. Therefore, longer periods of treatment may have
beneficial effects for nervous tissue regardless of the level of
plasmalogens restoration.
In adult Pex7 KO mice, despite a considerable pathology in
target tissues (e.g. testis and adipose tissue) the treatment with AG
was able to halt the progression of the disease and allow tissue
regeneration. An exception was the eye, in which the destruction
of the lens fibers and formation of a cataract prior to the start of
the treatment could not be reverted by the AG diet (data not
shown). In young Pex7 KO pups, the partial restoration of
plasmalogen levels in systemic tissues was most likely due to the
inability of AG to cross the placenta barrier and to be secreted in
milk [40]. Consequently, the pups ingested the AG diet for a
period of only six days. Nevertheless, these results also demonstrate
that within a week of treatment, most systemic tissues have
reached approximately 50% of WT levels. The study of the major
affected tissues in these young pups (i.e., eye and testis), revealed
that the AG diet could prevent the testicular degeneration and the
cataract formation. Of interest was the correlation between
plasmalogen levels and cataract formation, suggesting that at least
half the normal levels of plasmalogen are required to prevent the
development of cataracts. In RCDP patients, similar results were
obtained from the study of patients with mild and severe forms.
Patients with milder forms lacking the rhizomelia and cataracts,
usually have plasmalogen levels that amount to approximately 35–
45% of control levels [28].
In summary, our findings indicate that the Pex7 KO mouse is an
appropriate model to test and evaluate agents aimed at restoring
ether-phospholipids. Moreover, our results showed that the AG, 1-
O-octadecyl-rac-glycerol, can be used in vivo to restore plasmalogen
levels in peripheral organs and to halt or prevent pathological
alterations caused by plasmalogen deficiency. Our results in vitro
also showed that AG can be used to rescue the lipid droplet defects
caused by the deficiency in plasmalogens. Our data raises the
Figure 5. Plasmalogen levels after AG treatment in young mice. Plasmalogen levels in several tissues from 20-days old (P20) mice fed a
control diet (WT pups n=4; Pex7 KO pups n=4) or an AG diet (WT pups n=5; Pex7 KO pups n=6). Increased levels of plasmalogens are observed in
kidney, testis, eye and intestine.
doi:10.1371/journal.pone.0028539.g005
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its ability to correct plasmalogen levels in disorders caused or
modulated by a deficiency in plasmalogens, which ranges from the
genetic defects in etherphospholipid biosynthesis to Alzheimer’s
disease. In addition, our work should also drive the design and
evaluation of synthetic plasmalogens [61] or other plasmalogen
precursors in order to restore ether-phospholipid levels in disorders
where a deficiency in ether-phospholipids causes or modulates the
disease state.
Materials and Methods
Animals
Pex7 KO mice and littermate WT mice in a Swiss Webster
background were obtained by mating Pex7 heterozygous mice
and genotyped as described previously [42]. Gnpat KO mice [43]
were kindly provided by Prof. W. Just (Heidelberg, Germany) and
have been backcrossed to Swiss Webster for 7 generations. Mice
were housed under standard conditions and had free access to
Figure 6. AG treatment in young mice prevents tissue pathology. (A) Testis sections of P20 WT and Pex7 KO pups stained with hematoxylin
and eosin (H&E). Whereas control-fed Pex7 KO pups already showed the degenerative changes in spermatocytes, AG-fed Pex7 KO pups where
protected from degeneration and showed normal appearing seminiferous tubules and spermatocytes. Bars are 50 mm. (B) Eye sections of P20 WT and
Pex7 KO pups stained with Richardson’s stain. In contrast to the lens of WT pups showing organized and orientated fiber cells, the cataract in the lens
of control-fed Pex7 KO pups shows abnormally sized and abnormally arranged fiber cells. The AG diet prevented the abnormal development of fiber
cells in Pex7 KO pups thus preventing cataract formation. Bars are 50 mm. (C) Eye sections of mice showing the correlation between plasmalogen (Pls)
levels and the development of cataracts in Pex7 KO pups (from each mouse one eye was used for histology and the other eye used for biochemical
analyses). Whereas complete loss of plasmalogens (Pls=0.0) leads to a massive cataract occupying the entire lens (the cataract area is circled with a
dashed line), a plasmalogen level of 2.7% is able to prevent cataract formation in Pex7 KO pups. Partial restoration of plasmalogens (Pls=1.2%) leads
a small nuclear cataract (circled with a dashed line). Sections were stained as in (B) and bars are 100 mm. Numbers of mice analyzed: on control diet
WT mice n=4 and Pex7 KO mice n=4, on AG diet WT mice n=4 and Pex7 KO mice n=6.
doi:10.1371/journal.pone.0028539.g006
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with 100mg/kg ketamine and 10mg/kg xylazine. Blood was
collected by cardiac puncture and isolated organs were snap-
frozen in liquid nitrogen and stored at 280uC for further
analyses. To determine food consumption, WT and Pex7 KO
mice (n=5 for each genotype) were individually housed and the
weight of the food pellets was measured every morning during a
period of 10 days. Experiments and mouse manipulations were
approved by the Animals Experiments Committee of the
University of Amsterdam (GMZ11 ID100351 and GMZ1011
ID100924) and by the Direc ¸a ˜o Geral de Veterina ´ria (DGV;
project 011852).
Diet study
Alkyl-glycerol supplemented diets containing 2% 1-O-octadecyl-
rac-glycerol (Sigma-Aldrich) dissolved in ethanol and the control
diets lacking alkyl-glycerol were either manufactured by Ab Diets
(Woerden, the Netherlands) or, home-made by spraying the
solutions onto standard diet (Transbreed diet from Special Diets
Services, UK). During the process of spraying special care was
taken to ensure that the solution penetrated the food pellets (the
food pellets were rotated and soaked to allow for an even
distribution of the solution). The ethanol was allowed to evaporate
before supplying the diets to the animals.
For the treatment of adult mice, six-week-old mice were fed the
control or the AG-diet for 2 and 4 months. Food intake was
monitored by visual inspection of food pellet consumption and
body weights were determined twice a week. For the treatment of
pre-weaned pups, mating pairs were fed the control or the AG diet
from the day of the mating until the pups were 20-days old.
Cell culture and lipid droplet analyses
Mouse embryonic fibroblasts (MEFs) were isolated from E13.5
WT and Gnpat KO embryos as described [42]. MEFs were
cultured in DMEM (Sigma-Aldrich) supplemented with 10% fetal
bovine serum and 1x penicillin:streptomycin solution (Gibco).
MEFs from WT (n=4) and Gnpat KO mice (n=4) at passage 4,
were seeded onto glass coverslides in 24-well plates and treated for
7 days with 15 mMo f1 - O-octadecyl-rac-glycerol. An equal volume
of ethanol (vehicle for AG) was added to control-treated cultures of
WT and Gnpat KO MEFs.
Lipid droplets in MEFs were visualized after staining with
BODIPY 493/503 (Invitrogen). Briefly, cells were fixed with 2%
paraformaldehyde for 15 min. After washing in PBS, cells were
incubated with BODIPY 493/503 (1:500 dilution of a 1mg/ml
solution) for 15 min. After washing in PBS, cells were mounted on
a drop of Vectashield containing DAPI (Vector Labs).
The morphometric analyses of lipid droplets [62] was carried
out on z-stacks taken at 63x on a AxioImager Z1 microscope
with a 500 mm z-stack step. Images were deconvolved using the
quick maximum likelihood estimation (QMLE) algorithm from
Huygens Professional (HP) software (Scientific Volume Imaging,
Hilversum, The Netherlands). The deconvolved z-stacks were
analyzed for number and volume with the object analyzer
function of the HP software. These parameters were calculated
by the quantifications of all voxels contained in each z-stack and
all detected objects were automatically labeled and sent to a
continuous Iso Surface Ray tracing renderer. All images shown
in Figure 3 are maximum intensity projections (MIP) using the
HP renderer option, as described previously [63]. For the
untreated cells, 20 photos of each cell line were taken. For
control- and AG-treated cells, 40 photos of each cell line were
taken.
Biochemical and western blot analyses
Tissues were homogenized in PBS by sonication. The
homogenates were cleared by centrifugation at 900xg for
5 minutes and protein was measured using the DC Protein Assay
kit (Bio-Rad) using BSA as standard. Lysates corresponding to
300 mg of protein were used to measure plasmalogens. Plasmal-
ogens were measured as their dimethylacetal derivatives (DMA) by
gas chromatography and expressed as the ratio between C18:0
DMA and methylstearate (C18:0) as previously described [64].
White and brown adipose tissues were isolated from WT and
Pex7 KO mice (n=3 per genotype) and lysates were prepared by
sonication in PBS containing 0.1% triton X100 and protease
inhibitor cocktail (Roche). Protein samples (20ug) were separated
on 12.5% SDS-PAGE gels and transferred onto Hybond-C extra
membranes (Amersham Biosciences). Membranes were blocked
with 10% skim dried milk (Fluka) in PBS containing 0.01%
Tween20 and probed with antibodies rabbit anti-UCP1 (Abcam)
and mouse anti-b-actin (Sigma-Aldrich). Membranes were devel-
oped with ECL after incubation with horseradish peroxidase-
labeled secondary antibodies.
Histological analyses
Pieces of harvested tissues were fixed by immersion in buffered
formalin at 4uC for 48 hours, processed for paraffin embedding
and sectioned on a Leica RM2255 microtome, according to
routine practices. Paraffin sections, 5 mm thick, were deparaffi-
nized in Histoclear II (National Diagnostics), rehydrated using
decreasing concentrations of ethanol and used for routine
hematoxylin and eosin histological analyses. After fixation, eyes
were processed for LR White embedding (Electron Microscopy
Sciences) and semi-thin 1 mm sections were cut with a glass knife.
Eye sections were stained with Richardson’s stain (1:1 mixture of
1% methylene blue in 1% borax with 1% azure II), dried and
mounted with DPX. All sections were analyzed in a Zeiss
Axiophot microscope equipped with a Leica DFC320 camera.
For staining lipids, pieces of Harderian gland and brown adipose
tissue were fixed in 4% glutaraldehyde in 0.1M sodium cacodylate
buffer pH 7.6. Tissues were washed in sodium cacodylate buffer,
osmicated, dehydrated and embedded in Embed-812. One mm thin
sections were cut on a Leica ultramicrotome, and stained with p-
phenylenediamine (PPD; 1% solution in methanol). Sections were
washed with 95% ethanol, dried and mounted with DPX.
Electrophysiology
Mice from each genotype and treatment group (n$3) were
anesthetized as described above, and placed on a warm pad at a
temperature of 30-34oC. Recordings of compound muscle action
potentials (CMAP) were obtained on a PowerLab 4/25T (AD
instruments) using Chart5 software [33]. Recording needle
electrodes were placed subcutaneously in the foot pad and
supramaximal stimulation of sciatic nerves was performed distally
at the level of the ankle and proximally at the sciatic notch.
Conduction velocities were calculated as: (proximal distance –
distal distance)/(proximal latency – distal latency), with latencies
corresponding to the time lapse between the stimulus and the
onset of the CMAP and expressed in m/s.
Statistical analysis
All values are expressed as mean 6 standard deviation.
Statistical comparisons between two experimental groups were
evaluated using the Mann Whitney test from the statistical package
included in the GraphPad Prism5 software. We considered a p
value ,0.05 as significant.
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